Atomoxetine and Hydroxyzine: Safe to Take Together with Important Precautions
Yes, atomoxetine (Strattera) and hydroxyzine (Vistaril) can generally be taken together, but this combination requires careful monitoring due to the risk of QT interval prolongation and potential additive cardiovascular effects.
Key Safety Considerations
QT Prolongation Risk
Both medications carry warnings about QT interval prolongation, which is the primary concern when combining them:
Hydroxyzine is specifically listed as a QT-interval-prolonging medication in pediatric guidelines 1, with FDA labeling warning about QT prolongation and Torsade de Pointes, particularly in patients with other risk factors 2
Atomoxetine shows slight increases in QTc interval with increased drug concentration, though a dedicated cardiac study failed to demonstrate definitive QT prolongation 3
The FDA label for hydroxyzine explicitly states caution is recommended during concomitant use of drugs known to prolong the QT interval 2. While atomoxetine is not definitively classified as QT-prolonging, the combination warrants monitoring.
Cardiovascular Monitoring Requirements
Before initiating this combination:
- Obtain personal and family cardiac history (sudden death, long QT syndrome, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy) 4
- Consider baseline ECG, especially if risk factors are present 4
- Monitor heart rate and blood pressure, as atomoxetine typically increases both (average 1-2 bpm HR increase, 1-4 mmHg BP increase) 4
- Hydroxyzine may cause bradycardia and hypotension 2
Additional Considerations
CNS Depression: Hydroxyzine potentiates CNS depressants 2. While atomoxetine is not primarily a CNS depressant, it can cause somnolence 5, 4. Patients should be warned about:
- Increased drowsiness or sedation
- Avoiding driving or operating dangerous machinery until effects are known
- Not combining with alcohol or other CNS depressants 2
Metabolic Pathway: Atomoxetine is metabolized primarily via CYP2D6 5, 3, while hydroxyzine's metabolism is not significantly affected by this pathway. No direct pharmacokinetic interaction is expected, and atomoxetine does not inhibit or induce CYP enzymes 6.
Clinical Implementation Algorithm
Pre-treatment assessment:
- Screen for cardiac risk factors and family history
- Obtain baseline vital signs (HR, BP)
- Consider ECG if any cardiac risk factors present
Initiation:
- Start with standard dosing for each medication
- Educate patient/family about warning signs (palpitations, syncope, dizziness)
Monitoring:
- Regular vital sign checks during dose titration
- Monitor for excessive sedation or CNS effects
- Watch for cardiac symptoms (chest pain, syncope, palpitations)
Red flags requiring immediate evaluation:
- Syncope or near-syncope
- Palpitations or irregular heartbeat
- Chest pain
- Severe dizziness
Common Pitfalls to Avoid
- Don't ignore cardiac history: Even without obvious risk factors, obtain thorough personal and family cardiac history before combining these medications
- Don't overlook elderly patients: If used in older patients, start with low doses and monitor closely for sedation and cardiovascular effects 2
- Don't forget about electrolyte abnormalities: Correct any electrolyte imbalances (particularly potassium and magnesium) before initiating therapy, as these increase QT prolongation risk 1
The combination is used in clinical practice, particularly when treating ADHD with comorbid anxiety or sleep issues, but requires appropriate cardiovascular screening and ongoing monitoring for safety.